FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

Molecular and Cellular Pediatrics is a leading journal published by SPRINGERNATURE, dedicated to advancing knowledge in the fields of pediatrics, perinatology, and child health through innovative molecular and cellular research. Since its transition to Open Access in 2014, the journal has facilitated widespread dissemination of critical findings, making it accessible to a global audience of researchers, healthcare professionals, and students. The journal's scope encompasses a range of topics that explore the intersection of molecular biology and pediatric medicine, aiming to bridge gaps in our understanding of child health and development. With Scopus rankings placing it at the 48th percentile in pediatrics and a significant focus on cutting-edge research, Molecular and Cellular Pediatrics plays an essential role in shaping future research and clinical practices in the field. Its commitment to academic rigor and accessibility makes it a vital resource for those dedicated to improving pediatric health outcomes.

CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

SEMINARS IN THROMBOSIS AND HEMOSTASIS is a prestigious academic journal dedicated to advancing the understanding and practice of thrombosis and hemostasis, published by THIEME MEDICAL PUBL INC. With an ISSN of 0094-6176 and an E-ISSN of 1098-9064, this journal plays a critical role in disseminating groundbreaking research and reviews in the fields of cardiology and hematology. As of 2023, it holds a commendable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Hematology categories, with Scopus ranks of #55 out of 387 and #23 out of 137, respectively, positioning it within the top percentiles of these disciplines. The journal publishes articles that bring forth innovative findings and facilitate clinical applications, making it an essential resource for researchers, healthcare professionals, and students focused on improving patient care and outcomes. Since its inception in 1974, SEMINARS IN THROMBOSIS AND HEMOSTASIS continues to evolve with the changing landscape of medical research, striving to fill the gaps in knowledge and foster an informed approach to hemostatic disorders.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.